anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic kidney disease (CKD) can cause gut microbiota dysbiosis and decreasing production of short-chain fatty acids (SCFAs), which aggravate the injury of kidney. It has been found that a variety of Chinese medicine polysaccharides can regulate gut microbiota, especially probiotics, and have beneficial effects on human health. Astragalus polysaccharide (APS) is a major component of Astragalus aceus. The aim of this study was to investigate whether APS can regulate gut microbiota-SCFAs to slow the progression of CKD. Adenine-induced CKD mice (Ade) were established and APS was treated. The renal protection of APS on CKD mice was evaluated by renal function and pathological staining of renal tissues. Feces samples were collected for 16SrRNA sequence and LC-MS/MS analysis. Kidney G protein-coupled receptor (GPR) levels were also detected in renal tissue. APS supplementation can reduce serum creatinine and urea nitrogen levels in mice model (Ade) and attenuate renal tubular interstitial injury and renal fibrosis. Further application of 16SrRNA sequencing showed that the abundance of SCFA producing bacteria, such as Kineothrix, Faecalibaculum, Akkermansia, Lactobacillus, and Roseburia, was upregulated after APS treatment. Fecal LC-MS/MS detection showed that the levels of acetate, propionate and butyrate in Ade mice increased after APS supplementation. The detection of renal GPRs showed that APS supplementing could significantly increase the levels of renal GPR41 and GPR43, and also partially increase the levels of GPR109a in Ade mice. Our research confirms that APS supplementation can upregulate the abundance of SCFA producing bacteria and increase SCFA levels to attenuate renal tubular interstitial injury and fibrosis via GPRs.
BACKGROUND AND IMPORTANCE: The use of drains, including suction drains in neurosurgery is individual preference-based, rather than scientific evidence-based. Furthermore, the use of suction drains has been associated with significant risks to patients, including sudden death.
CLINICAL PRESENTATION: We present 2 cases of unfortunate sudden deaths following uneventful cranioplasty procedures, both of which were associated with the use of a suction drain. We also review the literature focusing on the benefits and risks in the use of suction drains, and discuss pathophysiological mechanisms underlying sudden death associated with their use.
CONCLUSION: There is no substantial evidence to support the use of suction drains in neurosurgery. Furthermore, they have been associated with significant complications, including risk to life. Our experience and literature review suggest that the risk of sudden death is disproportionately higher following cranioplasty. We do not recommend the use of suction drains in cranial neurosurgery, and we strongly recommend against their use in cranioplasty procedures.
An implantable device for intratumoral delivery of a therapeutic agent is provided. The implantable device includes a polymer matrix within which is dispersed a pharmaceutical formulation that includes one or more therapeutic agents. The therapeutic agent(s) includes one or more antibodies. Optionally, the polymer matrix includes one or more excipients. The polymer matrix includes a hydrophobic polymer. The hydrophobic polymer has a melt flow index of from about 0.2 to about 100 grams per 10 minutes as determined in accordance with ASTM D1238-20 at a temperature of 190°C and a load of 2.16 kilograms and/or a melting temperature of from about 20°C to about 70°C as determined in accordance with ASTM D3418-21.
A recent study has introduced a recombinant fusion protein, consisting of the extracellular domain (ECD) of p75 and the Fc fragment of human immunoglobulin IgG1 (p75ECD-Fc), as a multifaceted agent within the nervous system. This research aimed to assess the effects of p75ECD-Fc on neuronal growth and the restoration of neurological functions in rats afflicted with neonatal hypoxic-ischemic encephalopathy (NHIE). In vitro analyses revealed that 1 μM p75ECD-Fc treatment markedly increased cell viability and facilitated neurite outgrowth in neurons exposed to oxygen-glucose deprivation (OGD). Subsequent in vivo studies determined that a dose of 78.6 μg/3 μl of p75ECD-Fc significantly mitigated brain damage and both acute and long-term neurological impairments, outperforming the therapeutic efficacy of hypothermia, as evidenced through behavioral assessments. Additionally, in vivo immunostaining showed that p75ECD-Fc administration enhanced neuronal survival and regeneration, and reduced astrocytosis and microglia activation in the cortex and hippocampus of NHIE rats. A noteworthy shift from A1 to A2 astrocyte phenotypes and from M1 to M2 microglia phenotypes was observed after p75ECD-Fc treatment. Furthermore, a co-expression of the p75 neurotrophin receptor (p75NTR) and Nestin was identified, with an overexpression of Nestin alleviating the neurological dysfunction induced by NHIE. Mechanistically, the neuroprotective effects of p75ECD-Fc, particularly its inhibition of neuronal apoptosis post-OGD, may be attributed to Nestin. Taken together, these results highlight the neuroprotective and anti-inflammatory effects of p75ECD-Fc treatment through the modulation of glial cell phenotypes and the Nestin-mediated inhibition of neuronal apoptosis, positioning it as a viable therapeutic approach for NHIE.
The invention provides an application of phlorizin in preparing a medicament for delaying aging and treating aging diseases. The molecular formula of the phlorizin is C21H24O10. Researches of the invention find out that the phlorizin can markedly prolong the service life of yeast, the phlorizin has oxidation resisting property, and the oxidative stress is resisted by regulating SOD (Superoxide Dismutase), the expression of Sir2/SIRT1 genes and the activity of enzymes so as to prolong the service life of the yeast; and the phlorizin can improve the SIRT1 enzyme activity with the Sir2 homologue of the yeast, and the SIRT1 performs an important action on prolonging the service life of mammals. In the invention, the anti-aging effect of the phlorizin at a food source place and the action mechanism thereof are reached by applying the replicative service-life analysis of the biological model. i.e. the yeast of anti-aging chemical researches for the first time. The invention provides the application of the phlorizin in preparing the medicament for delaying the aging and treating the aging diseases. The invention provides the application of the phlorizin in preparing nutrient substances for delaying the aging and preventing or assisting in treating the aging diseases.
The present invention concerns a flavouring composition containing flavonoids of onion, tea, and/or apple. T he composition is characterized by containing flavor of mustard seeds, preferably powder and/or extract of mustard. Further, the invention discloses a p process for the preparation of the flavouring composition and food product s containing the flavouring composition according to the invention. Also several uses of the flavouring composition are disclosed, such as t he use of a flavoring composition containing flavonoids for the cosmetic treatment of a mammal to cause loss of body weight. Further, t he invention discloses the use of the flavour of mustard seeds, preferably mustard powder or extract, for preventing the bitter taste of flavonoids. I n a further embodiment the invention discloses a method for preventing the bitter taste of a medicament, a nutrient, a drink, a food or a food additive caused by flavonoids.
Over the past decade, the use of biometrics in security systems and other applications has grown in popularity. ECG signals in particular are attracting increased attention due to their characteristics, which are required for a trustworthy identification system. The majority of ECG-based person identification systems are evaluated without considering the health-state of the individuals. Few person identification systems consider person-by-person health-state annotation. This paper proposes a person identification system considering the health-state annotated ECG signals where each person's beats overlap among variant arrhythmia classes. This overlapping between the normal class and other arrhythmia classes grants the ability to isolate normal beats in the train set from the Arrhythmic beats in the test set. Therefore, this paper investigates the effect of arrhythmic heartbeats on biometric recognition. An effective lightweight CNN based on depth-wise separable convolution (DWSC) is proposed to enhance the performance of person identification for several common arrhythmia types using the MITBIH dataset. The proposed methodology has been tested on nine arrhythmia types and presents how different types of arrhythmia affect ECG-based biometric systems differently. The experimental results show excellent recognition performance (99.28%) on normal heartbeats and (93.81%) on arrhythmic heartbeats, outperforming other models in terms of mean accuracy.
The invention discloses a sinomenine vesicle and a preparation method thereof, a preparation containing the sinomenine vesicle and a preparation method of the preparation, which belong to the field of medicament preparations. The sinomenine vesicle is prepared from sinomenine, a nonionic surfactant and an additive. The sinomenine vesicle is preferably prepared into external gel. A sinomenine transdermal administration external preparation has a unique advantage to the medicament. Due to the application of a novel vesicle administration system, transdermal absorption of the medicament is improved, and a clinical curative effect is enhanced. The sinomenine vesicle can be used for treating rheumatism, rheumatoid arthritis, a glomerular disease, hyperosteogeny, spondylitis, arrhythmia, systemic lupus erythematosus, a heroin addict withdrawal symptom and the like.
A pilot cohort follow-up study is proposed based on the viability of a tele-physiotherapy program preoperative respiratory thoracic surgery for pulmonary cancer. The Patient selection will be done over a period of 2 months between January and February 2022, without participant limit during this period. The patient will have two face-to-face visits where the assessments and data will be collected. During follow-up patients will do 3-4 video conferencing with the principal investigator. For 3-4 weeks the patients will use the FISSIOS App to follow up of the exercises every day. The study will be conducted at the HSCSP in Barcelona. The results will be analyzed by the Epidemiology of the Hospital de Sant Pau
Novel antiobesity medications, particularly glucagon-like peptide-1 receptor agonists (GLP-1RAs), have expanded weight loss (WL) options for kidney transplantation (KT) candidates with obesity beyond lifestyle modifications and bariatric surgery. However, varying effectiveness, risk profiles, and costs make strategy choices challenging. To aid decision-making, we used a Markov model to examine the cost-effectiveness of different WL strategies over a 10-year horizon. A target WL of 15% of total body weight was used for the base case scenario, and we compared these strategies to a "liberal" KT strategy of transplanting candidates with obesity. Outcomes included costs (2023 US dollars), quality-adjusted life years, and incremental cost-effectiveness ratios. In analysis, a liberal KT strategy was favored over lifestyle modifications and GLP-1RAs. Among WL strategies, bariatric surgery was the most effective and cost the least, whereas lifestyle modification had the highest cumulative costs and was the least effective. Compared to liberal KT, bariatric surgery costs $45 859 per quality-adjusted life year gained. GLP-1RAs were favored over bariatric surgery only when drug costs were below $5000 per year (base cost $12 077). In conclusion, for KT candidates with obesity, a liberal KT strategy and bariatric surgery are preferred over lifestyle modifications alone and GLP-1RAs based on outcomes and cost-effectiveness.
BACKGROUND: There is growing evidence that an antioxidant diet is a protective factor against frailty. However, few studies have examined the effect of comprehensive dietary antioxidants on frailty symptoms. The aim of this study was to examine the relationships between the composite dietary antioxidant index (CDAI) and frailty and the underlying mechanisms involved.
METHODS: Based on the National Health and Nutrition Survey (NHANES) 2003-2018, this study included 11,277 older persons aged ≥60 years. In this study, frailty was defined as having a total score >0.21 on the 49-item frailty index. Six dietary antioxidants were selected for use in calculating the CDAI. A weighted multiple logistic regression model with subgroup analysis and restricted cubic splines (RCSs) were used to examine the association between the CDAI and frailty. To examine the role of oxidative stress, mediation analyses were also conducted.
RESULTS: The association between the CDAI score and frailty risk was significant according to the multivariate model. Compared with participants in tertile 1, participants in both tertile 2 and tertile 3 had lower odds of developing frailty symptoms (OR=0.86; 95% CI=0.75-0.97; P=0.02; and OR=0.81; 95% CI=0.70-0.93; P=0.003). According to the subgroup analyses, the differences in interactions were not statistically significant. There was also a potential nonlinear relationship between the CDAI score and frailty risk. The serum albumin concentration and uric acid concentration had significant mediating effects on the association between the CDAI score and frailty index, with 19.25% (P=0.002) and 21.26% (P < 0.001) of the total, respectively.
CONCLUSION: Frailty is negatively associated with the CDAI score, which may be partially mediated by oxidative stress.
The cpd. of formula (I) is made by (a) dissolving 1 mol imidazole in 75 ml. 85% lactic acid (b) stirring for 30 mins. at 45 deg. C and (c) cooling until it crystallises. - The solid is suitable for local application in concns. of 5-10% to prevent lipolysis of triglycerides present in the cutaneous undergrowth, its pH making it very suitable to prevent their hydrolysis.
Methods: Study participation will not influence any element of IVF treatment and all participants will be receiving the standard of care at Boston IVF. Potential participants will be identified by a member of the research team, who will review the appointment log and medical records to ensure eligibility. Eligible participants interested in participating in the study will have an abdominal ultrasound endometrial thickness measurement on the day of the participants embryo transfer (T2). This abdominal ultrasound is part of routine clinical care necessary for the embryo transfer. The eligible participant will provide verbal consent to a member of the research team prior to the ultrasound. Baseline demographic data will be obtained from the electronic medical record including: age, race, education level, partner status, height, weight, gravidity, and parity.

Two groups of thaw cycles will be included: (1) exogenous hormone replacement thaw cycles and (2) modified natural thaw cycle. Both groups will follow the standard of care for cycle preparation at Boston IVF. Ultrasound measurements of the endometrial lining (T1) will only be used if they were within 1 day of the initiation of progesterone (group 1) or ovulation trigger injection (group 2). At T1, multiple endometrial lining measurements will be made per standard protocol, but only the optimal image and measurement will be saved. At T2, only a single endometrial thickness measurement will be measured by the sonographer and will be recorded on a study log. Images should include a longitudinal view of the endometrium and cervix. Measurements from the T2 ultrasound will be blinded from the participant and they will not be used to make any clinical decisions. Both groups will have a comparison of the difference in endometrial thickness measurement between T1 and T2.

Sample Size Justification: Given the limited data on this specific topic, the study will be an observational pilot study. Given the available resources, the researchers will aim to have 100 participants per cycle preparation group, for a total of 200 participants.

Data Analysis: Descriptive data will be presented as the proportion, mean with standard deviation, or median with interquartile range. Comparisons will be made using the chi-square or Fisher's exact test for categorical variables and parametric or non-parametric tests for continuous variables based on data distribution. Logistic regression analysis will be performed for multivariate analysis. All data will be analyzed with SAS 9.4 (SAS Institute Inc., Cary, NC, USA). All tests will be two sided and a P value \< 0.05 will be required to confer significance.
FIELD: medicine. ^ SUBSTANCE: invention relates to oral compositions. Composition contains the following components: a) whitening agent; and b) acrylic film-forming polymer, which represents thermal polymer. The first monomer link of thermal polymer is selected from the group including acrylic acid, methacrylic acid and their combination. The second monomer link of thermal polymer is selected from the group including acrylates, acrylamides, acetates and their combination. The third monomer link is either selected from group including acrylates, acrylamides, acetates and their combinations, or is selected from group including siloxanes, vinyl esters of C5-C12-alcohols and their combinations. One of preferable thermal polymers is thermal polymer of tret-butyl-acrylate, ethyl acrylate and methacrylic acid. Preferably, composition additionally contains lower alcohol such as ethanol. ^ EFFECT: composition formula provides for stability of whitening agent, such as peroxide, in storage, and high efficiency of whitening. ^ 15 cl, 6 tbl, 6 ex
The invention discloses a 2-(3,4-dimethoxy)benzoyl-5-(4-substituted phenylethynyl) thiophene. The structural formula of the 2-(3,4-dimethoxy)benzoyl-5-(4-Substituted phenylethynyl) thiophene is as shown in the specification. The preparation method of the 2-(3,4-dimethoxy)benzoyl-5-(4-Substituted phenylethynyl) thiophene comprises the following steps: 1) reacting 2-bromothiophene with 3,4-dimethoxybenzoyl in a solvent in the presence of a catalyst and then carrying out purification and separation to obtain 2-(3,4-dimethoxy)benzoyl-5-bromothiophene; 2) reacting the 2-(3,4-dimethoxy)benzoyl-5-bromothiophene with 4-substituted phenylacetylene in a solvent in the presence of tetra(triphenylphosphine) palladium, CuI and an acid-binding agent, and then carrying out subsequent purification and separation. The invention also relates to application of the compound in preparation of anti-breast cancer targeted treatment drugs, and an application of the compound in preparation of anti-breast cancer resistance-reversal agents. The compound has relatively obvious proliferation inhibition effect on human breast cancer cells and breast cancer cell drug-resistant strains, and thus can be applied to preparation of the anti-breast cancer targeted treatment drug and the anti-breast cancer resistance-reversal agent. The compound has the potential of large-scale industrial production and relatively low cost.
People sick with infectious illnesses face negative social outcomes, like exclusion, and may take steps to conceal their illnesses from others. In 10 studies of past, current, and projected illness, we examined the prevalence and predictors of infection concealment in adult samples of U.S. university students, health-care employees, and online crowdsourced workers (total N = 4,110). About 75% reported concealing illness in interpersonal interactions, possibly placing others in harm's way. Concealment motives were largely social (e.g., wanting to attend events like parties) and achievement oriented (e.g., completing work objectives). Disease characteristics, including potential harm and illness immediacy, also influenced concealment decisions. People imagining harmful (vs. mild) infections concealed illness less frequently, whereas participants who were actually sick concealed frequently regardless of illness harm, suggesting state-specific biases underlying concealment decisions. Disease concealment appears to be a widely prevalent behavior by which concealers trade off risks to others in favor of their own goals, creating potentially important public-health consequences.
Patients receive palifosfamide IV over 30 minutes on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Rectus-Intercostal Fascial Plane Block: Aseptic conditions are ensured in the area where the block will be performed. With the patient in the supine position and under ultrasound (USG) guidance, a linear probe is placed 2-3 cm lateral and caudal to the xiphoid process to visualize the rectus abdominis muscle and the 6th-7th costal cartilages. Using an in-plane technique, the needle is advanced from caudal to cephalad. After confirming the target by hydrodissecting between the ribs and the rectus abdominis muscle, 20 ml of 0.25% bupivacaine is injected into the interfascial plane between the 6th-7th ribs and the rectus abdominis muscle using a 22-G, 80 mm block needle. The same procedure is then applied to the opposite side.
Participants will be instructed to take 17 grams of powder PEG\* every day for 7 days starting the day of surgery. Participants will be allowed to titrate up or down the amount of PEG used as needed and instructed to record all doses of PEG used.
Multiple sclerosis (MS) is primarily a disease diagnosed in young and middle-aged adults. Although MS is a rare condition in pediatric age, an increasing rate of patients is diagnosed under the age of 18. The disabling nature of the disease cannot be reduced only to physical symptoms. Several additional symptoms such as cognitive impairment, fatigue, and psychological symptoms are common features of pediatric MS. The reviewed literature suggests that, despite the lower physical disability, children and adolescents diagnosed with MS are vulnerable to cognitive impairment even in the early stage of the disease. The neuropsychological profile of pediatric MS may resemble that of adult MS, including an impairment in attention/information processing speed, learning, verbal, and visuospatial memory. However, cognitive difficulties in children and adolescents are more likely to involve also general intelligence and linguistic abilities, presumably due to patients' younger age and cognitive growth stage. Cognitive difficulties, beyond physical disability and relapses, may have a considerable impact on learning and school achievement. Depression and fatigue are other highly prevalent disturbances in pediatric MS and may contribute to patients' low functional outcomes. Overall, these manifestations may cause considerable functional impairment on daily activities and quality of life that may require individualized rehabilitative treatment and extensive psychosocial care. Additional neuropsychological research evaluating larger samples, using more homogenous methods, and exploring the role of MS treatment on cognitive and psychological development is required.